| Vifor (International) Inc. - Flucelvax, Injektionssuspension in einer Fertigspritze | | 70144 | | 01 | | Flucelvax | | Injektionssuspension in einer Fertigspritze | | J07BB02 | | Influenza, gereinigtes Antigen | | 29.04.2026 | | |
| | Zusammensetzung | | haemagglutininum influenzae A (H1N1) (Virus Stamm A/Wisconsin/67/2022 (H1N1)-like: derived from A/Georgia/12/2022 CVR-167) 15 µg, haemagglutininum influenzae A (H3N2) (Virus Stamm A/Massachusetts/18/2022 (H3N2)-like: derived from A/Sydney/1304/2022) 15 µg, haemagglutininum influenzae B (Virus Stamm B/Austria/1359417/2021-like: reassortant from B/Singapore/WUH4618/2021 (Victoria lineage)) 15 µg, natrii chloridum, kalii chloridum, magnesii chloridum hexahydricum, natrii dihydrogenophosphas dihydricus, kalii dihydrogenophosphas, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml corresp. natrium 1.74 mg, kalium 0.1 mg, residui: polysorbatum 80, cetrimidum, propiolactonum. | | Packungsbestandteile | | Injektionssuspension in einer Fertigspritze | | | | | | Wirkstoffe | Stärke |
|---|
| Haemagglutininum Influenzae a (H1N1) (Virus Stamm A/wisconsin/67/2022 (H1N1)-Like: Derived from A/georgia/12/2022 Cvr-167) | 15µg / 0.5ml | | Haemagglutininum Influenzae a (H3N2) (Virus Stamm A/massachusetts/18/2022 (H3N2)-Like: Derived from A/sydney/1304/2022) | 15µg / 0.5ml | | Haemagglutininum Influenzae b (Virus Stamm B/austria/1359417/2021-Like: Reassortant from B/singapore/wuh4618/2021 (Victoria Lineage)) | 15µg / 0.5ml |
| | | | Hilfsstoffe |
|---|
| Kalii Chloridum | | Kalii Dihydrogenophosphas | | Magnesii Chloridum Hexahydricum | | Natrii Chloridum | | Natrii Dihydrogenophosphas Dihydricus |
|
| | Packungsnummer | Packungsgrösse | EFP | PP | Kat. | SL | In Refdata nicht gelistet |
|---|
| 001 | | | | B | | Ja | | 002 | 10 | | | B | | Ja | | 003 | | | | B | | Ja | | 004 | 10 | | | B | | Ja |
|
|
